Oxaprozin

From Wikipedia, the free encyclopedia - View original article

Oxaprozin
Oxaprozin.svg
Systematic (IUPAC) name
3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
Clinical data
Trade namesDaypro
AHFS/Drugs.commonograph
MedlinePlusa693002
Pregnancy cat.C
Legal statusPrescription Only (S4) (AU) rx only
RoutesOral
Pharmacokinetic data
Bioavailability95%
Protein binding99%
MetabolismLiver—65% oxidation and 35% glucuronic acid conjugation. 5% are active phenolic metabolites.
Half-life54.9 hours
Identifiers
CAS number21256-18-8 YesY
ATC codeM01AE12
PubChemCID 4614
DrugBankDB00991
ChemSpider4453 YesY
UNIIMHJ80W9LRB YesY
KEGGD00463 YesY
ChEBICHEBI:7822 N
ChEMBLCHEMBL1071 YesY
Chemical data
FormulaC18H15NO3 
Mol. mass293.317 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Oxaprozin
Oxaprozin.svg
Systematic (IUPAC) name
3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
Clinical data
Trade namesDaypro
AHFS/Drugs.commonograph
MedlinePlusa693002
Pregnancy cat.C
Legal statusPrescription Only (S4) (AU) rx only
RoutesOral
Pharmacokinetic data
Bioavailability95%
Protein binding99%
MetabolismLiver—65% oxidation and 35% glucuronic acid conjugation. 5% are active phenolic metabolites.
Half-life54.9 hours
Identifiers
CAS number21256-18-8 YesY
ATC codeM01AE12
PubChemCID 4614
DrugBankDB00991
ChemSpider4453 YesY
UNIIMHJ80W9LRB YesY
KEGGD00463 YesY
ChEBICHEBI:7822 N
ChEMBLCHEMBL1071 YesY
Chemical data
FormulaC18H15NO3 
Mol. mass293.317 g/mol
 N (what is this?)  (verify)

Oxaprozin, also known as Oxaprozinum, (sold under the names: Daypro, Dayrun, Duraprox) is a non-steroidal anti-inflammatory drug (NSAID),[1] used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. It is available in 600 mg tablets. Normal adult dosage is 1200 mg daily, not to exceed 1800 mg per day. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.

References[edit]

  1. ^ Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, Shader RI (March 1985). "Oxaprozin pharmacokinetics in the elderly". British Journal of Clinical Pharmacology 19 (3): 373–8. doi:10.1111/j.1365-2125.1985.tb02656.x. PMC 1463728. PMID 3986088.